Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process

International Journal of Nanomedicine

Volumn 6, Issue , 2011, Pages 2997-3009

  Kim, Min Soo ^a   Kim, Jeong Soo ^a   Park, Hee Jun ^a   Cho, Won Kyung ^a,b   Cha, Kwang Ho ^a,b   Hwang, Sung Joo ^b  

^a Chungnam National University   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Bioavailability; Nanoparticles; Sirolimus; Solubility; Supercritical antisolvent

Indexed keywords

NANOPARTICLE; RAPAMYCIN; DRUG CARRIER; POVIDONE; SURFACTANT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG BIOAVAILABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR STABILITY; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PHYSICAL PARAMETERS; RAT; SOLUBILITY; SUPERCRITICAL ANTISOLVENT PROCESS; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION; ANALYSIS OF VARIANCE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG STABILITY; METHODOLOGY; NANOTECHNOLOGY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG STABILITY; MALE; NANOPARTICLES; NANOTECHNOLOGY; POVIDONE; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

MLCS; MLOWN;

EID: 84862631967     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S26546     Document Type: Article

References (38)

1. Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28:721–726.
2. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998;31:335–340.
3. Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213:25–29.
4. Rouf MA, Bilensoy E, Vuralİ, Hincal AA. Determination of stability of rapamycin following exposure to different conditions. Euro J Pharm Sci. 2007;32(1 Suppl 1):S46.
5. Rouf MA, Bilensoy E, Vuralİ, Hincal AA. Inclusion complexation of rapamycin with beta-cyclodextrin to improve solubility and stability of the drug. The 2nd BBBB Conference on Pharmaceutical Sciences, September 13–15, 2007, Tallinn-Tartu, Estonia.
6. Buech G, Bertelmann E, Pleyer U, Siebenbrodt I, Borchert HH. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther. 2007;23:292–303.
7. Alemdar AY, Sadle D, McAlister VC, Mendez I. Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant. 2004;13:263–271.
8. Rosen H, Abribat T. The rise and rise of drug delivery. Nat Rev Drug Discov. 2005;4:381–385.
9. Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomed. 2008;3:295–310.
10. Preetham AC, Satish CS. Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution. J Disp Sci Technol. 2011;32:778–783.
11. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12:1068–1075.
12. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Euro J Pharm Biopharm. 2000;50:47–60.
13. Srinarong P, de Waard H, Frijlink HW, Hinrichs WLJ. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations. Expert Opin Drug Deliv. 2011;8:1121–1140.
14. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 1999;88:1058–1066.
15. Janssens S, Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol. 2009;61:1571–1586.
16. Craig DQ. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231:131–144.
17. Karavas E, Georgarakis E, Sigalas MP, Avgoustakis K, Bikiaris D. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions. Euro J Pharm Biopharm. 2007;66:334–347.
18. Won DH, Kim MS, Lee S, Park JS, Hwang SJ. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm. 2005;301:199–208.
19. Jun SW, Kim MS, Jo GH, et al. Cefuroxime axetil solid dispersions prepared using solution enhanced dispersion by supercritical fluids. J Pharm Pharmacol. 2005;57:1529–1537.
20. Jun SW, Kim MS, Kim JS, et al. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2007;66: 413–421.
21. Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: a review. Int J Nanomed. 2011;6:1429–1442.
22. Fages J, Lochard H, Letourneau JJ, Sauceau M, Rodier E. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol. 2004;141:219–226.
23. Pasquali I, Bettini R, Giordano F. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics. Euro J Pharm Sci. 2006;27:299–310.
24. Ricciutelli M, Di Martino P, Barboni L, Martelli S. Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC. J Pharm Biomed Anal. 2006;41:1070–1074.
25. Wang X, Venkatraman SS, Boey FY, Loo JSC, Tan LP. Controlled release of sirolimus from a multilayered PLGA stent matrix. Biomaterials. 2006;27: 5588–5595.
26. Paine MF, Leung LY, Lim HK, et al. Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion. J Pharmacol Exp Ther. 2002;301:174–186.
27. Kim MS, Jin SJ, Kim JS, et al. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm. 2008;69: 454–465.
28. Streit F, Christians U, Schiebel UM, Meyer A, Sewing KF. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos. 1996;24:1272–1278.
29. Maleki S, Graves S, Becker S, et al. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin Ther. 2000;22 Suppl B:B25–B27.
30. Wacher VJ, Silverman JA, Wong S, et al. Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther. 2002;303:308–313.
31. Juppo AM, Boissier C, Khoo C. Evaluation of solid dispersion particles prepared with SEDS. Int J Pharm. 2003;250:385–401.
32. Kim MS, Kim JS, Hwang SJ. Enhancement of wettability and dissolution properties of cilostazol using the supercritical antisolvent process: effect of various additives. Chem Pharm Bull. 2010;58:230–233.
33. Alonzo DE, Gao Y, Zhou D, Mo H, Zhang GGZ, Taylor LS. Dissolution and precipitation behavior of amorphous solid dispersions. J Pharm Sci. 2011;100:3316–3331.
34. Konno H, Handa T, Alonzo DE, Taylor LS. Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine. Eur J Pharm Biopharm. 2008;70:493–499.
35. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U. Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther. 1998;285:1104–1112.
36. Paine MF, Leung LY, Watkins PB. New insights into drug absorption: studies with sirolimus. Ther Drug Monit. 2004;26:463–467.
37. Cummins CL, Jacobsen W, Christians U, Benet LZ. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther.2004;308: 143–155.
38. Abu-Diak OA, Jones DS, Andrews GP. An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations. Mol Pharm.2011;8:1362–1371.